Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Background: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as indepen...

全面介绍

书目详细资料

发表在:	EBioMedicine
Main Authors:	Hao Sun, Si-Yang Liu, Jia-Ying Zhou, Jin-Tian Xu, Huang-Kai Zhang, Hong-Hong Yan, Jiao-Jiao Huan, Ping-Ping Dai, Chong-Rui Xu, Jian Su, Yan-Fang Guan, Xin Yi, Rong-Shan Yu, Wen-Zhao Zhong, Yi-Long Wu
格式:	文件
语言:	英语
出版:	Elsevier 2020-10-01
主题:	TP53 Lung adenocarcinoma Immunotherapy Subtypes
在线阅读:	http://www.sciencedirect.com/science/article/pii/S2352396420303662